Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of Obicetrapib and Ezetimibe in Healthy Adults
NCT06547359Phase 1Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of obicetrapib in hypercholesterolemia (2 arms), sponsored by NewAmsterdam Pharma. Primary endpoints: Maximum Plasma Concentration up to 18 days, Area Under the Curve to Last Measurable Concentration up to 18 days and 1 more. Started Oct 2024; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06547359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547359.